News and Trends 11 Jul 2022 Study results reveal bleeding episodes are significantly reduced by hemophilia drug People suffering from a severe blood disorder may only have to take a once-monthly drug following successful results from an ongoing study. Global healthcare company, Sanofi, has been conducting a study into fitusiran prophylaxis and results have shown it reduces bleeds by 61 per cent in people with hemophilia A or B, with or without […] July 11, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jul 2022 New drug application for treatment of dry eyes disease submitted to FDA A treatment for dry eye symptoms associated with Meibomian gland dysfunction (MGD) has been submitted under a New Drug Application (NDA) and will be considered by the US Food and Drug Administration. The application was submitted at the end of last month (June) by the Canada-based global eye health company, Bausch and Lomb Corporation, and […] July 8, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jul 2022 Cancer therapeutics company’s double win with $25M funding, and appointment of new board member An mRNA-technology company developing cancer therapeutics designed to improve patients’ survival rate and quality of life — this week announced the completion of a $25 million Series A financing. Kernal Biologics, Inc. (Kernal Bio) confirmed that the funding was led by Hummingbird Ventures. Amgen Ventures, HBM Genomics and Civilization Ventures along with other venture capitalists, family offices and […] July 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jul 2022 Biosyntia closes a €11.5M round to launch world’s first bio-based vitamin B7 A bio-based vitamin B7 is the first product to be commercialized as biotech company, Biosyntia, secures funding from a strong syndicate of capital investors. Biosyntia, manufactures sustainable and natural ingredients using precision fermentation and has a strong pipeline of active ingredients for use in beauty and nutrition products such as vitamins and antioxidants. A funding […] July 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jul 2022 Biotech food colorant startup Phytolon seals $14.5M in funding Phytolon, a developer of fermentation-based natural food colors, has secured $14.5 million in funding, led by DSM Venturing, to further progress its technology towards commercialization. Other participation came from Cibus Fund, Ginkgo Bioworks (in-kind investment in the form of Foundry services) and The Trendlines Agrifood Fund. Participation in the series A funding also includes some […] July 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 8 Jul 2022Beyond Biotech podcast 4: CorePath, Rensselaer, Versameb This week’s guests are: Helen Zha, assistant professor of chemical and biological engineering and a member of the Center for Biotechnology and Interdisciplinary Studies (CBIS) at Rensselaer Polytechnic Institute; Versameb CEO Klaas Zuideveld; and Aamir Ehsan, CEO and medical director of CorePath and Celina Villa, medical director of Biopharma Division. Versameb gives presentation during World […] July 8, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jul 2022 World’s first research project for an early detection, multi-cancer screening test launched in Singapore A project for the discovery and validation of new combinations of biomarkers that can detect multi-cancer early has been launched in Singapore. Biotechnology company, MiRXES Ptr Ltd, announced this week the signing of a memorandum of understanding signaling the launch of Project CADENCE (Cancer Detected Early caN be CurEd). It is the world’s first large-scale […] July 8, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2022 Treatments set to improve for lethal lung disease and ulcers following drug synergy data revelation New data has been published today (July 7) evidencing findings that could lead to better treatment for people with lethal lung infections and infected diabetic foot ulcers caused by antimicrobial resistant (AMR) bacteria. Clinical stage biotechnology company, Destiny Pharma plc., focused on the development of novel products to prevent life-threatening infections, revealed the publication of […] July 7, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2022 French Juvisé buys gastro product in €400M finance deal French pharmaceutical company, Juvisé has just bought worldwide commercial rights to Pylera from US biopharmaceutical company Abbvie. Juvisé negotiated financing of €400 million ($408 million) with Société Générale as part of the deal and also the refinancing of its existing debt. Pylera is an antimicrobial tri-therapy that helps gastro-intestinal Helicobacter pylori infections. Lazard and Latham […] July 7, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2022 Vaccizone chooses partner to fast-track development of COVID-19 vaccine A vaccine development company has chosen a partner to fast-track the development of its SARS-CoV-2 product for European clinical trials. Vaccizone has chosen viral vector contract development and manufacturing company (CDMO) antigen delivery technology Exothera S.A to accelerate the vaccine. Vaccizone is the inventor of the ASC Technology, a first-in-class antigen delivery platform for generating […] July 7, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jul 2022 Finnish and US companies form exclusive agreement for development of sustained release drug A sustained release drug that can help people with age-related macular degeneration (AMD) has been given a global license agreement. DelSiTech and Iveric Bio have announced the agreement so Iveric Bio can develop and commercialize new formulations of drug Zimura (avacincaptad pegol) using DelSiTech’s silica-based sustained release technology. As part of Iveric Bio’s lifecycle expansion […] July 6, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jul 2022 Exyte Builds mRNA Competence Center for WACKER in Germany A messenger ribonucleic acid (mRNA) competence center is being built at the Halle Biotech site of German company Wacker Chemie AG (WACKER). Exyte GmbH is a global design, engineering company that delivers facilities for high-tech industries and is in charge of the site at WACKER. The project is making a considerable contribution towards strengthening the […] July 6, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email